This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Jan 24;8(2):62.

doi: 10.1038/nrneurol.2012.2.

Neurodevelopmental disorders: Unsilencing dormant Ube3a--hope for Angelman syndrome?

PMID: 22270025
DOI: 10.1038/nrneurol.2012.2

Comment

Neurodevelopmental disorders: Unsilencing dormant Ube3a--hope for Angelman syndrome?

Katy Malpass. Nat Rev Neurol. 2012.

. 2012 Jan 24;8(2):62.

doi: 10.1038/nrneurol.2012.2.

Author

PMID: 22270025
DOI: 10.1038/nrneurol.2012.2

No abstract available

PubMed Disclaimer

Comment on

Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons.
Huang HS, Allen JA, Mabb AM, King IF, Miriyala J, Taylor-Blake B, Sciaky N, Dutton JW Jr, Lee HM, Chen X, Jin J, Bridges AS, Zylka MJ, Roth BL, Philpot BD. Huang HS, et al. Nature. 2011 Dec 21;481(7380):185-9. doi: 10.1038/nature10726. Nature. 2011. PMID: 22190039 Free PMC article.

Similar articles

Towards a therapy for Angelman syndrome by targeting a long non-coding RNA.
Meng L, Ward AJ, Chun S, Bennett CF, Beaudet AL, Rigo F. Meng L, et al. Nature. 2015 Feb 19;518(7539):409-12. doi: 10.1038/nature13975. Epub 2014 Dec 1. Nature. 2015. PMID: 25470045 Free PMC article.
CRISPR/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice.
Schmid RS, Deng X, Panikker P, Msackyi M, Breton C, Wilson JM. Schmid RS, et al. J Clin Invest. 2021 Mar 1;131(5):e142574. doi: 10.1172/JCI142574. J Clin Invest. 2021. PMID: 33411694 Free PMC article.
Angelman syndrome: advancing the research frontier of neurodevelopmental disorders.
Philpot BD, Thompson CE, Franco L, Williams CA. Philpot BD, et al. J Neurodev Disord. 2011 Mar;3(1):50-6. doi: 10.1007/s11689-010-9066-z. Epub 2010 Dec 3. J Neurodev Disord. 2011. PMID: 21484597 Free PMC article.
Gene Therapy for Angelman Syndrome: Contemporary Approaches and Future Endeavors.
Tsagkaris C, Papakosta V, Miranda AV, Zacharopoulou L, Danilchenko V, Matiashova L, Dhar A. Tsagkaris C, et al. Curr Gene Ther. 2020;19(6):359-366. doi: 10.2174/1566523220666200107151025. Curr Gene Ther. 2020. PMID: 31914913 Review.
From UBE3A to Angelman syndrome: a substrate perspective.
Sell GL, Margolis SS. Sell GL, et al. Front Neurosci. 2015 Sep 15;9:322. doi: 10.3389/fnins.2015.00322. eCollection 2015. Front Neurosci. 2015. PMID: 26441497 Free PMC article. Review.

See all similar articles

Cited by

Simvastatin Restores HDAC1/2 Activity and Improves Behavioral Deficits in Angelman Syndrome Model Mouse.
Kumar V, Joshi T, Vatsa N, Singh BK, Jana NR. Kumar V, et al. Front Mol Neurosci. 2019 Nov 26;12:289. doi: 10.3389/fnmol.2019.00289. eCollection 2019. Front Mol Neurosci. 2019. PMID: 31849603 Free PMC article.
Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman Syndrome.
Copping NA, McTighe SM, Fink KD, Silverman JL. Copping NA, et al. Neurotherapeutics. 2021 Jul;18(3):1535-1547. doi: 10.1007/s13311-021-01082-x. Epub 2021 Sep 15. Neurotherapeutics. 2021. PMID: 34528170 Free PMC article. Review.

References

1. Nature. 2011 Dec 21;481(7380):185-9 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.